Trials / Terminated
TerminatedNCT02882841
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients (MOBIDIC)
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- Enterome · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is a multicenter, international descriptive study with a bio-collection in 300 evaluable Crohn's disease patients to be processed after usual biological tests via bioinformatics tools. At this time, this study has no impact neither on treatment nor on disease diagnostic, these will be based on usual medical practices and is no investigational product associated with the conduct of this study.
Detailed description
350 Crohn's disease patients will be included in the study, targeting 300 evaluable patients. An interim analysis will be performed after 50% of the evaluable patients are recruited. The primary objective is to evaluate the relation between non-invasive biomarkers (host immunological variables and metagenomic analysis in stools) and AIEC detection in biopsies taken during an endoscopy, in order to develop a predictive algorithm of AIEC carriage. The secondary objectives are: * Validation of the AIEC detection algorithm using qPCR technology. * Assessment of the correlation between the presence of AIEC and the endoscopic and clinical evaluations of the disease (CDEIS, SES-CD, Harvey-Bradshaw Index and Crohn's Disease Activity Index). * Development and validation of a non-invasive qPCR based diagnostic of Mucosal Healing in CD patients. * Collection of biological samples associated with all clinical and biological data from CD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Biopsies, stool and blood collection |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2016-08-30
- Last updated
- 2018-06-12
Locations
3 sites across 3 countries: United States, France, United Kingdom
Source: ClinicalTrials.gov record NCT02882841. Inclusion in this directory is not an endorsement.